Please login to the form below

Not currently logged in
Email:
Password:

warfarin

This page shows the latest warfarin news and features for those working in and with pharma, biotech and healthcare.

Xarelto no better than aspirin in secondary stroke study

Xarelto no better than aspirin in secondary stroke study

The overall NOAC market is growing strongly in the face of a string of new studies showing the new drugs' benefits over older anticoagulants such as warfarin, but Xarelto has seen

Latest news

  • Xarelto beats aspirin for recurrent blood clots Xarelto beats aspirin for recurrent blood clots

    Meanwhile, the overall NOAC market is growing strongly in the face of a string of new studies showing the new drugs' benefits over older anticoagulants such as warfarin.

  • Bayer defends Xarelto as pivotal trial scrutinised Bayer defends Xarelto as pivotal trial scrutinised

    The trial used a device called INRatio, manufactured by Alere, to determine whether doses of warfarin should be adjusted to keep the drug in the right therapeutic range. ... The implication is that patients on warfarin may have been more prone to bleeds

  • Daiichi Sankyo licenses clot-busting antibody Daiichi Sankyo licenses clot-busting antibody

    Meanwhile, anticoagulants such as warfarin and the newer novel oral anticoagulant (NOAC) class can prevent clots from forming but are unable to dissolve them when already present.

  • NICE recommends Daiichi Sankyo's Lixiana for DVT and PE NICE recommends Daiichi Sankyo's Lixiana for DVT and PE

    around £26, 000 per quality-adjusted life year (QALY), though it noted there are no definitive costs for warfarin monitoring. ... In terms of its clinical effectiveness Daiichi said Lixiana proven efficacy and a significantly better bleeding profile

  • Daiichi’s new anticoagulant recommended by NICE Daiichi’s new anticoagulant recommended by NICE

    warfarin that patients and physicians appreciate.”. ... The first OAC, which was approved more than 50 years ago, is the generic warfarin, but in recent years a spate of new drugs has come onto the market for AF

More from news
Approximately 1 fully matching, plus 71 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics